Oxford Nanopore Technologies PLC ONT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- GBX 153.40
- Day Range
- GBX 151.60–156.90
- 52-Week Range
- GBX 85.00–229.40
- Bid/Ask
- GBX 150.00 / GBX 189.00
- Market Cap
- GBX 142.66 Bil
- Volume/Avg
- 1.8 Mil / 1.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.69
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,281
- Website
- https://www.nanoporetech.com
Comparables
Valuation
|
Metric
|
ONT
|
002030
|
688468
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 12.70 | 21.05 |
Price/Book Value | 3.60 | 1.07 | 2.05 |
Price/Sales | 7.69 | 8.73 | 6.16 |
Price/Cash Flow | — | 15.08 | 14.42 |
Price/Earnings
ONT
002030
688468
Financial Strength
|
Metric
|
ONT
|
002030
|
688468
|
|---|---|---|---|
Quick Ratio | 3.36 | 2.15 | 4.71 |
Current Ratio | 4.45 | 4.15 | 5.48 |
Interest Coverage | −55.35 | −78.04 | 111.54 |
Quick Ratio
ONT
002030
688468
Profitability
|
Metric
|
ONT
|
002030
|
688468
|
|---|---|---|---|
Return on Assets (Normalized) | −16.92% | −5.89% | 7.46% |
Return on Equity (Normalized) | −30.33% | −7.30% | 9.59% |
Return on Invested Capital (Normalized) | −21.10% | −7.42% | 7.98% |
Return on Assets
ONT
002030
688468
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Gmjwzhfxbr | Fvp | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Drjkfrxl | Zqqvhh | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dstxphxgp | Jbzzy | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Sfpntrzw | Bnjcdg | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Tykwbrdm | Fnfd | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Rzbvfxzq | Lskn | $29.2 Bil | |||
| Moderna Inc
MRNA
| Gpqcmgln | Hbxf | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Dfgwknbpj | Nzb | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ptcbxythw | Qyymvs | $13.2 Bil | |||
| Incyte Corp
INCY
| Stgbcyjfr | Pzhqlck | $13.0 Bil |
United States